Brief: Anavex Life Sciences Requests EMA To Re-Examine Blarcamesine For Alzheimer's
18/12/2025 12:38
Dec 18 (Reuters) - Anavex Life Sciences Corp AVXL.O: ANAVEX LIFE SCIENCES CORP - REQUESTS EMA TO RE-EXAMINE BLARCAMESINE FOR ALZHEIMER'S Source text: ID:nGNX32fF0l Further company coverage: AVXL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board